Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974228 | 0.91 | MEN1 (0.41) | RAB9AMEN1KMT2A | |
| SCHEMBL4972012 | 0.88 | ALDH1A1 (0.41) | L3MBTL1RAB9AMEN1KMT2A | |
| SCHEMBL4970522 | 0.86 | HRH3 (0.40) | L3MBTL1PPARD | |
| SCHEMBL4969649 | 0.83 | HPGD (0.43) | L3MBTL1MEN1KMT2A | |
| SCHEMBL5158591 | 0.82 | L3MBTL1 (0.46) | ATML3MBTL1RAB9AMEN1KMT2A | |
| SCHEMBL4975262 | 0.82 | HSD17B10 (0.44) | RAB9AMEN1KMT2A | |
| SCHEMBL4740754 | 0.81 | MAPK1 (0.44) | MEN1KMT2A | |
| SCHEMBL4972770 | 0.81 | TDP2 (0.52) | CAMK2AMEN1KMT2A | |
| SCHEMBL4973505 | 0.80 | KDM4E (0.46) | MEN1KMT2APPARD | |
| SCHEMBL4970874 | 0.78 | GRM5 (0.39) | L3MBTL1MEN1KMT2APPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008118790-A1 | DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| US-20080234327-A1 | DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234327-A1 | DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS | FECH, SLC40A1, HAMP | ATM 4493/4885L3MBTL1 1737/4885CAMK2A 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.